Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

ICB wants to build a clearing infrastructure for international settlements

10/9/23 CBOM

Fesco increased transportation by Far East cabotage services by 4%

10/9/23 FESH

Positive Technologies introduced a new product for endpoint protection

10/9/23 POSI

Acron to increase calcium nitrate production 2.5 times

10/9/23 AKRN

Yango is up and running in Colombia

10/9/23 YNDX

Bristol Myers buys Mirati Therapeutics

10/9/23 MRTX

Sitronics Group has tested its first hydrogen-powered vessel

10/9/23 AFKS

Sergey Gordeev no longer owns a controlling stake in PIK

10/9/23 PIKK

Lockheed Martin announced a quarterly dividend

10/9/23 LMT

GELEO became the owner of Novatek's Polish assets

10/6/23 NVTK